top of page
overlay.png

Stay Informed About Your Health

Get physician-written articles on hormone optimization, metabolic health, healthy aging, sexual wellness and the science of living well.  New educational content delivered directly to your mailbox.

Thanks for subscribing!

HRT Is First-Line Treatment for Menopause Symptoms. Why Are So Many Doctors Still Hesitant?

Writer: Dr. Jackson
Dr. Jackson
Nov 2
8 min read

ACOG's new menopause guidelines reinforce what the evidence has shown for years. So why are women still struggling to get treatment?


In October 2026, the American College of Obstetricians and Gynecologists (ACOG) released updated clinical guidelines recommending systemic menopausal hormone therapy as a first-line treatment for hot flashes and night sweats in women without contraindications.


As a physician who has spent more than 25 years caring for women, I welcome this recommendation. But I also find myself asking why it has taken so long for the medical community to move beyond the fear surrounding hormone replacement therapy.


For years, I've seen women struggle with symptoms that affect their sleep, concentration, relationships, and ability to function at work. Some have been told their symptoms are simply part of getting older. Others have asked about hormone therapy only to be told it is too dangerous.


Meanwhile, our understanding of hormone therapy has continued to evolve.

The new ACOG guideline is an important opportunity to examine how we arrived here, what the evidence actually tells us, and why so many physicians remain uncomfortable prescribing hormones.


Menopause and HRT

What Does ACOG's New Menopause Guideline Actually Recommend?


On October 15, 2026, ACOG published Clinical Practice Guideline No. 13, replacing its previous menopause treatment bulletin from 2014.


The updated guideline gives a strong recommendation for systemic menopausal hormone therapy to treat vasomotor symptoms, which include hot flashes and night sweats, in women who do not have contraindications.


ACOG also recommends systemic hormone therapy for sleep disturbances associated with these symptoms.


The guideline emphasizes several important points:

  • Hormone therapy is an effective treatment for hot flashes and night sweats. Estrogen is generally combined with a progestogen when the uterus is present to protect the endometrium.

  • Timing influences the balance of benefits and risks. ACOG recommends initiating treatment before age 60 or within 10 years of menopause onset in appropriate candidates.

  • Treatment decisions should be individualized. Age, medical history, cardiovascular risk, formulation, route of administration, and patient preferences all influence treatment choices.

  • Treatment duration should be reassessed rather than dictated by an arbitrary stopping age.

  • Nonhormonal options remain important. These include certain antidepressants and neurokinin receptor antagonists for women who cannot or prefer not to use hormones.


ACOG's 2014 guideline already recognized systemic estrogen therapy as the most effective treatment for menopausal hot flashes. The Menopause Society has also supported appropriate hormone therapy for years.


For a more comprehensive understanding of menopause, hormone changes, and the treatment options available, explore my Complete Guide to Menopause and Hormone Optimization


Yet the hesitation surrounding hormone therapy has persisted. To understand why, we have to go back to 2002.


How the Women's Health Initiative Changed Menopause Treatment


In 2002, the Women's Health Initiative (WHI) dramatically changed how physicians prescribed hormone therapy. The combined hormone trial was stopped early after identifying increased risks of breast cancer, blood clots, stroke, and cardiovascular events.

But several important details were lost in the headlines.


First, the study used oral conjugated equine estrogens and medroxyprogesterone acetate, a synthetic progestin. These differ from the estradiol and micronized progesterone commonly prescribed today. The average participant was also 63 years old, considerably older than many women seeking treatment when menopausal symptoms begin.


Second, the WHI included a separate estrogen-only trial involving women who had undergone hysterectomy. Long-term follow-up found a statistically significant reduction in breast cancer incidence and breast cancer mortality among women assigned to estrogen alone. These findings received far less public attention than the increased breast cancer risk reported in the combined hormone trial.


The WHI created widespread fear among both patients and physicians, fueled by misleading interpretations that applied the risks of specific hormone formulations to women of all ages and medical backgrounds. More than 20 years later, women are still paying the price through unnecessary suffering, missed treatment opportunities, and continued reluctance among physicians to prescribe hormone therapy.


The WHI studied hormone formulations that differ from the estradiol and micronized progesterone commonly prescribed today. Learn more about these differences and the available treatment options on my Bioidentical Hormone Replacement Therapy page.


Menopause and HRT


Why Are Some Doctors Still Reluctant to Prescribe HRT?


I don't believe there is a single explanation. Several factors have contributed to the continued hesitation.


1. The Fear Created by the WHI Has Been Difficult to Reverse


For many physicians, the fear surrounding hormone therapy became ingrained during their training and has persisted despite decades of additional research. Changing those beliefs requires physicians to actively reconsider what they were taught and incorporate newer evidence into their clinical decisions.


Later research has provided a more detailed understanding of those risks, including differences between estrogen-only and combined therapy and the importance of treatment timing.


But changing clinical habits requires more than publishing new evidence.


2. Menopause Has Not Received Enough Attention in Medical Training


Menopause affects virtually every woman who lives into midlife, yet many physicians receive limited dedicated training in its management.


Understanding when hormone therapy is appropriate requires familiarity with cardiovascular risk assessment, breast cancer risk, abnormal uterine bleeding, endometrial protection, and the differences among hormone preparations.


Fortunately, menopause education is receiving more attention, although progress has been slow. As someone involved in training medical students at Florida State University College of Medicine, I feel strongly about preparing future physicians to approach menopause with an understanding of current evidence rather than outdated fears.


I don't expect every physician to become a menopause specialist. A physician who rarely prescribes hormone therapy may reasonably feel less comfortable managing these decisions.


What I do expect is for physicians to recognize menopausal symptoms, understand that hormone therapy is a legitimate treatment option, and refer women to clinicians with menopause expertise when appropriate.


A lack of specialized training should never prevent a woman from receiving a balanced discussion of her treatment options.


3. Physicians Have Legitimate Concerns About Safety


Some women should not receive systemic hormone therapy, and others require careful evaluation before treatment.


A history of breast cancer, unexplained vaginal bleeding, prior blood clots, stroke, or significant cardiovascular disease can substantially change the treatment discussion.

Those concerns should be taken seriously.


At the same time, a healthy 52-year-old woman experiencing disruptive hot flashes is not medically equivalent to a 72-year-old woman with established cardiovascular disease who wants to begin systemic estrogen for the first time.


Applying the same risk assessment to both women does not reflect the evidence.


4. Menopause Counseling Takes Time


A thoughtful hormone therapy consultation involves more than writing a prescription.


I want to understand your symptoms, when they began, your menstrual history, your medical and family history, your medications, and your personal priorities. I also want you to understand the potential benefits and risks of treatment so you can make an informed decision.


Unfortunately, our healthcare reimbursement system is largely structured around diagnosing and treating disease rather than optimizing health and quality of life. Although some counseling is reimbursable, physicians are often not adequately compensated for the time required to provide comprehensive menopause education.


When a physician has a limited appointment to address chronic medical conditions, preventive screenings, and other health concerns, finding additional time for an in-depth menopause discussion can be challenging.


I understand these pressures because I've practiced within this system for decades. But women shouldn't have to accept inadequate menopause care because our healthcare system fails to prioritize it.


When there isn't enough time for a thorough discussion, a referral to a clinician who specializes in menopause management may be the most appropriate next step.


What Has Changed in Our Understanding of Hormone Therapy?


One of the most important developments since the original WHI announcement is a better understanding of how the timing of treatment affects its risk-benefit profile.

For most healthy women who begin hormone therapy before age 60 or within 10 years of menopause onset, the benefits of treating bothersome vasomotor symptoms generally outweigh the risks.


This does not mean starting hormones at a younger age eliminates every risk. It means the overall balance is often more favorable than it is for women who begin treatment much later.


We also recognize that all hormone formulations should not be treated as interchangeable.

For example, transdermal estradiol avoids the first-pass effects of oral estrogen on the liver and may carry a lower risk of venous thromboembolism than oral estrogen, although much of the comparative safety evidence comes from observational studies.


The type of progestogen used for endometrial protection may also influence tolerability and risk.


These considerations allow physicians to make more individualized treatment decisions than a blanket recommendation to avoid hormones.


There are still unanswered questions, particularly about long-term outcomes with different formulations and treatment durations. Recognizing those uncertainties is part of responsible prescribing.


Menopause and HRT

What Should You Do if Your Doctor Is Hesitant to Prescribe Hormone Therapy?


If you're experiencing hot flashes, night sweats, or sleep disruption that affects your quality of life, you deserve to understand your treatment options.


Ask your physician whether you have a specific contraindication to systemic hormone therapy.


If hormone therapy is not recommended, ask which factors in your medical history influence that decision and what alternatives might be appropriate.


You can also ask whether the new ACOG guidance changes your treatment options.

If you receive only a general statement that hormones are dangerous, without a discussion of your individual risk factors, it is worth seeking an evaluation from a clinician experienced in menopause management.


If you're looking for a more individualized discussion of your symptoms and treatment options, you can schedule a hormone therapy consultation.


New Guidelines Are Only the Beginning


I'm encouraged that ACOG is taking a stronger position in support of hormone therapy for appropriate women. But updated guidelines alone won't reverse decades of fear and undertreatment.


A recent Mayo Clinic study found that only about 3.5% of insured American women ages 50–59 had filled prescriptions for at least six months of systemic hormone therapy in 2023. Meanwhile, CDC data show that nearly half of American women ages 40–60 experience menopausal symptoms, representing approximately 16.7 million women.


These figures illustrate an enormous gap between the number of women experiencing menopause symptoms and those receiving hormone therapy. Although not every symptomatic woman needs or wants hormones, many could benefit from a more informed discussion about treatment.


As physicians, we need to be stronger advocates for these women, challenge outdated misconceptions, and ensure they have access to appropriate menopause care.

Women have waited long enough.


Menopause and HRT


Frequently Asked Questions


Is HRT now the first-line treatment for hot flashes?

ACOG's October 2026 guideline gives systemic menopausal hormone therapy a strong recommendation for treating hot flashes and night sweats in women without contraindications. It is an important treatment option, particularly for appropriate candidates younger than 60 or within 10 years of menopause onset.


Did ACOG previously recommend against hormone therapy?

No. ACOG's 2014 guideline already recognized systemic estrogen therapy as the most effective treatment for menopausal vasomotor symptoms. The 2026 guideline updates the evidence and provides an explicit strong recommendation.


Does hormone therapy increase breast cancer risk?

Risk depends on the regimen, duration of use, and individual factors. In the WHI, combined oral estrogen and medroxyprogesterone acetate increased breast cancer incidence, while estrogen alone in women with prior hysterectomy had different findings. Individual counseling is important.


Is it too late to start HRT after age 60?

Starting systemic hormone therapy after age 60 or more than 10 years after menopause generally carries a less favorable risk-benefit profile. That does not mean every woman must discontinue therapy at age 60. Initiation and continuation are separate decisions that require individualized assessment.


What if I cannot take hormone therapy?

Nonhormonal prescription medications, including certain SSRIs/SNRIs and neurokinin receptor antagonists, can reduce vasomotor symptoms. Other approaches may help address associated sleep and mood symptoms.



References

  1. American College of Obstetricians and Gynecologists. Management of Menopause-Related Vasomotor, Sleep, and Mood Symptoms. Clinical Practice Guideline No. 13. Obstetrics & Gynecology. 2026;148:e345–e369.

  2. American College of Obstetricians and Gynecologists. Management of Menopausal Symptoms. Practice Bulletin No. 141. Obstetrics & Gynecology. 2014.

  3. The Women's Health Initiative randomized trials of menopausal hormone therapy and subsequent analyses of age, timing, and long-term outcomes.

  4. The Menopause Society. The 2022 Hormone Therapy Position Statement. Menopause. 2022.


Listen to Dr Jackson discuss these topics on her podcast, Ageless and Outrageous agelessandoutrageous.alitu.com


Ageless and Outrageous


 
 
 

Comments


bottom of page